Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;10(23):e40808.
doi: 10.1016/j.heliyon.2024.e40808. eCollection 2024 Dec 15.

Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment

Ana Hernández-Guío  1 , Miguel Ángel Calleja-Hernández  2 , Andrés Corno-Caparrós  3 , Marta Zayas-Soriano  1 , Mª Ángeles Bernabéu-Martínez  1 , Fernando Gutiérrez-Nicolás  4
Affiliations

Clinical impact of DPYD genotyping and dose adjustment in candidates for fluoropyrimidine treatment

Ana Hernández-Guío et al. Heliyon. .

Abstract

Image 1.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.

Figures

Image 1
Graphical abstract
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Amstutz U., Henricks L.M., Offer S.M., Barbarino J., Schellens J.H.M., Swen J.J., et al. Clinical pharmacogenetics implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. febrero de. 2018;103(2):210–216. - PMC - PubMed
    1. Henricks L.M., Lunenburg C.A.T.C., de Man F.M., Meulendijks D., Frederix G.W.J., Kienhuis E., et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. noviembre de. 2018;19(11):1459–1467. - PubMed
    1. Lunenburg C.A.T.C., van der Wouden C.H., Nijenhuis M., Crommentuijn-van Rhenen M.H., de Boer-Veger N.J., Buunk A.M., et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines. Eur. J. Hum. Genet. abril de 2020;28(4):508–517. - PMC - PubMed
    1. García-Alfonso P., Saiz-Rodríguez M., Mondéjar R., Salazar J., Páez D., Borobia A.M., et al. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol. marzo de. 2022;24(3):483–494. - PMC - PubMed
    1. Miarons M., Manzaneque Gordón A., Riera P., Gutiérrez Nicolás F., Collaboration with the RedDPYD Research Group with the Spanish Society of Hospital Pharmacy (SEFH) Abdel-Kader Martin L, et al. Allelic frequency of DPYD genetic variants in patients with cancer in Spain: the PhotoDPYD study. The Oncologist. 8 de mayo de. 2023;28(5):e304–e308. - PMC - PubMed

LinkOut - more resources